Clinical Trials
136 trialsKICKSTART
Effector Therapeutics
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
PILOT
The Affiliated Hospital of Qingdao University
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Henan Cancer Hospital
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Guangzhou University of Traditional Chinese Medicine
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Fujian Cancer Hospital
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage â…¢ NSCLC
Beijing Tsinghua Chang Gung Hospital
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
ECTOP-1004
Fudan University
A Single-arm Exploratory Study of Neoadjuvant Therapy
Guangzhou Institute of Respiratory Disease
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Three Gorges Hospital of Chongqing University
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
MILES-4
National Cancer Institute, Naples
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
National Hospital Organization Nagoya Medical Center
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shandong New Time Pharmaceutical Co., LTD
SPBPDC
Qianfoshan Hospital
TRUMP
Guangdong Association of Clinical Trials
CAP-BRAIN
Sun Yat-sen University
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
European Organisation for Research and Treatment of Cancer - EORTC
FTANLCNDG
Qianfoshan Hospital
Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis
The First Hospital of Jilin University
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Tianjin Medical University Cancer Institute and Hospital
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
Seoul St. Mary's Hospital
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
Peking Union Medical College
Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases
Shanghai Pudong Hospital
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
neoSCORE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)
Tang-Du Hospital
Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
NSABP Foundation Inc
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sichuan Cancer Hospital and Research Institute
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
Sun Yat-sen University
NACA
Sun Yat-sen University
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
The Netherlands Cancer Institute
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
The University of Hong Kong
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
Shanghai Chest Hospital
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
China Three Gorges University, Yichang, China
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
China Three Gorges University, Yichang, China
NEOSUN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
DYNAPET
Fifth Affiliated Hospital, Sun Yat-Sen University